Does coexisting accommodative dysfunction impact clinical convergence measures, symptoms and treatment success for symptomatic convergence insufficiency in children?
- PMID: 34730250
- PMCID: PMC10544663
- DOI: 10.1111/opo.12911
Does coexisting accommodative dysfunction impact clinical convergence measures, symptoms and treatment success for symptomatic convergence insufficiency in children?
Erratum in
-
Does coexisting accommodative dysfunction impact clinical convergence measures, symptoms and treatment success for symptomatic convergence insufficiency in children?Ophthalmic Physiol Opt. 2022 Nov;42(6):1412-1413. doi: 10.1111/opo.13052. Epub 2022 Sep 16. Ophthalmic Physiol Opt. 2022. PMID: 36111644 Free PMC article. No abstract available.
Abstract
Purpose: To determine whether coexisting accommodative dysfunction in children with symptomatic convergence insufficiency (CI) impacts presenting clinical convergence measures, symptoms and treatment success for CI.
Methods: Secondary data analyses of monocular accommodative amplitude (AA; push-up method), monocular accommodative facility (AF; ±2.00 D lens flippers) and symptoms (CI Symptom Survey [CISS]) in children with symptomatic CI from the Convergence Insufficiency Treatment Trial (N = 218) and CITT-Attention and Reading Trial (N = 302) were conducted. Decreased AA was defined as more than 2D below the minimum expected amplitude for age (15 - ¼ age); those with AA < 5 D were excluded. Decreased AF was defined as <6 cycles per minute. Mean near point of convergence (NPC), near positive fusional vergence (PFV) and symptoms (CISS) were compared between those with and without accommodative dysfunction using analysis of variance and independent samples t-testing. Logistic regression was used to compare the effect of baseline accommodative function on treatment success [defined using a composite of improvements in: (1) clinical convergence measures and symptoms (NPC, PFV and CISS scores) or (2) solely convergence measures (NPC and PFV)].
Results: Accommodative dysfunction was common in children with symptomatic CI (55% had decreased AA; 34% had decreased AF). NPC was significantly worse in those with decreased AA (mean difference = 6.1 cm; p < 0.001). Mean baseline CISS scores were slightly worse in children with coexisting accommodative dysfunction (decreased AA or AF) (30.2 points) than those with normal accommodation (26.9 points) (mean difference = 3.3 points; p < 0.001). Neither baseline accommodative function (p ≥ 0.12 for all) nor interaction of baseline accommodative function and treatment (p ≥ 0.50) were related to treatment success based on the two composite outcomes.
Conclusions: A coexisting accommodative dysfunction in children with symptomatic CI is associated with worse NPC, but it does not impact the severity of symptoms in a clinically meaningful way. Concurrent accommodative dysfunction does not impact treatment response for CI.
Keywords: accommodative facility; accommodative insufficiency; children; convergence insufficiency; ocular accommodation; symptoms.
© 2021 The Authors Ophthalmic and Physiological Optics © 2021 The College of Optometrists.
References
-
- Schor CM. Models of mutual interactions between accommodation and convergence. American journal of optometry and physiological optics. 1985;62(6):369–374. - PubMed
-
- Schor CM, Tsuetaki TK. Fatigue of accommodation and vergence modifies their mutual interactions. Investigative ophthalmology & visual science. 1987;28(8):1250–1259. - PubMed
-
- Rouse MW, Borsting E, Hyman L, et al. Frequency of convergence insufficiency among fifth and sixth graders. The Convergence Insufficiency and Reading Study (CIRS) group. Optometry and vision science : official publication of the American Academy of Optometry. 1999;76(9):643–649. - PubMed
-
- Borsting E, Rouse MW, Deland PN, et al. Association of symptoms and convergence and accommodative insufficiency in school-age children. Optometry. 2003;74(1):25–34. - PubMed
Publication types
MeSH terms
Grants and funding
- U10 EY022594/EY/NEI NIH HHS/United States
- U10 EY014709/EY/NEI NIH HHS/United States
- U10 EY022592/EY/NEI NIH HHS/United States
- U10 EY022601/EY/NEI NIH HHS/United States
- U10 EY022591/EY/NEI NIH HHS/United States
- U10 EY022596/EY/NEI NIH HHS/United States
- U10 EY014710/EY/NEI NIH HHS/United States
- U10 EY014716/EY/NEI NIH HHS/United States
- U10 EY014659/EY/NEI NIH HHS/United States
- U10 EY014712/EY/NEI NIH HHS/United States
- U10 EY022587/EY/NEI NIH HHS/United States
- U10 EY014676/EY/NEI NIH HHS/United States
- U10 EY014706/EY/NEI NIH HHS/United States
- 5U10EY022599/EY/NEI NIH HHS/United States
- U10 EY014713/EY/NEI NIH HHS/United States
- 5U10EY022601/EY/NEI NIH HHS/United States
- U10 EY022586/EY/NEI NIH HHS/United States
- U10 EY022599/EY/NEI NIH HHS/United States
- U10 EY014715/EY/NEI NIH HHS/United States
- U10 EY022595/EY/NEI NIH HHS/United States
- U10 EY022600/EY/NEI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical